Skip to main content
OpenTrials
Completed

NCT Number: NCT05915884

The Triglyceride/Glucose Index and SGLT-2 Inhibitors

This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital.

Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Metabolic Disease Diabetes Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Samsun Education and Research Hospital

Samsun, İlkadım, 55200, Turkey (Türkiye)

About this study

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated below, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 injection and the trig/glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients. Triglyceride, glucose, and glycosylated hemoglobin values were checked at the beginning of the treatment and at the 3rd-month follow-up.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 DM
  • Age >18 years old
  • Dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg
  • 3 months follow-up period

Exclusion criteria

  • Type 1 diabetes
  • Gestational diabetes
  • Age < 18 years old
  • Insufficient or missed laboratory test results
  • Medical treatment for dyslipidemia
  • Hypothyroidism

Treatment and study plan

SGLT-2 inhibitors

Other

This study is an observational study. It is not planned to do an interventional activity.

Primary outcomes

  1. Change in triglyceride index

    Time frame: 3 months

    Decreased triglyceride index among patients using SGLT-2 inhibitors.

Sponsors and collaborators

Lead sponsor

Samsun Education and Research Hospital

Other

Registry information

Official study title

Investigation of the Triglyceride/Glucose Index in Diabetic Patients Using SGLT-2 Inhibitor

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Jun 23, 2023
Registry last updated
Apr 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.